BLOOMAGE BIOTECHNOLOGY CORP LTD Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
華 熙 生 物 科 技 有 限 公 司
(incorporated in the Cayman Islands with limited liability)
(Stock Code: 00963)This announcement is made by Bloomage BioTechnology Corporation Limited (the "Company", together with its subsidiaries, the "Group") pursuant to the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules")) under Part XIVA of the Securities and Futures Ordinance and Rule 13.09 of the Listing Rules.
The board of the directors (the "Board") hereby informs the shareholders of the Company (the "Shareholders") and potential investors that, based on the preliminary review and assessment of the latest unaudited consolidated management accounts of the Group, it is expected that the Group will record a year-on-year increase in sales income exceeding 30% for the period ended 31 December 2015, which mainly benefits from the gradual implementation of the products diversification strategy for the medical beauty ecological chain formed by the Group.
In order to better implement the products diversification strategy for the medical beauty ecological chain, and keep its leading position in the PRC medical beauty industry and sustainable growth of future results, in 2015, the Company has undertaken certain overseas investment and acquisition and financing projects, and entered into agreements to issue management subscription shares to the core management, which incurred a series of extra fees and expenses and accounting impacts, including 1) one-off intermediary expense in respect of investment and acquisition and financial project; 2) equity settled share-based payment expense arising from the management subscription shares to be issued; 3) amortization of intangible assets arising from acquisition projects; 4) interest expenses arising from financing. It is expected that the above expense and accounting impacts in aggregate will exceed RMB50,000,000.00, which would affect the overall net profits of the Company for the financial year ended 31 December 2015.
The Company is still in the process of finalising the results of the Group for the year ended 31 December 2015. The information contained in this announcement is only based on preliminary assessment made by the Board with reference to the latest unaudited consolidated management accounts of the Group for the period, which are subject to adjustments as appropriate and further review by the Company and its auditors.
Shareholders and potential investors are advised to read carefully the final results announcement of the Group for the financial year ended 31 December 2015 for further details, which is expected to be announced by end of March 2016.
Hong Kong, 4 January 2016
By Order of the Board
Bloomage BioTechnology Corporation Limited ZHAO YANChairman
As at the date of this announcement, the executive Directors are Ms. Zhao Yan, Mr. Jin Xuekun, Ms. Liu Aihua and Ms. Wang Aihua; the non-executive Director is Mr. Guo Jiajun; the independent non-executive Directors are Ms. Zhan Lili, Mr. Hai Wen and Mr. Li Junhong.
Bloomage BioTechnology Corporation Ltd. issued this content on 2016-01-04 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-04 10:23:07 UTC
Original Document: http://www.bloomagebio-tech.com/attachment/2016010418020200002401581_en.pdf
